Neoleukin Therapeutics Stock Working Capital
| NLTXDelisted Stock | USD 0.69 0.01 1.43% |
Neoleukin Therapeutics fundamentals help investors to digest information that contributes to Neoleukin Therapeutics' financial success or failures. It also enables traders to predict the movement of Neoleukin Stock. The fundamental analysis module provides a way to measure Neoleukin Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neoleukin Therapeutics stock.
Neoleukin |
Neoleukin Therapeutics Company Working Capital Analysis
Neoleukin Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Neoleukin Therapeutics Working Capital | 88.07 M |
Most of Neoleukin Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neoleukin Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionBased on the company's disclosures, Neoleukin Therapeutics has a Working Capital of 88.07 M. This is 79.31% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The working capital for all United States stocks is 94.04% higher than that of the company.
Neoleukin Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neoleukin Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neoleukin Therapeutics could also be used in its relative valuation, which is a method of valuing Neoleukin Therapeutics by comparing valuation metrics of similar companies.Neoleukin Therapeutics is currently under evaluation in working capital category among its peers.
Neoleukin Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | (35.02 M) | |||
| Shares Outstanding | 2.35 M | |||
| Shares Owned By Insiders | 16.46 % | |||
| Shares Owned By Institutions | 45.58 % | |||
| Number Of Shares Shorted | 26.4 K | |||
| Price To Earning | (4.60) X | |||
| Price To Book | 0.44 X | |||
| EBITDA | (56.48 M) | |||
| Net Income | (57.56 M) | |||
| Cash And Equivalents | 116.46 M | |||
| Cash Per Share | 2.73 X | |||
| Total Debt | 12.07 M | |||
| Debt To Equity | 0.11 % | |||
| Current Ratio | 12.78 X | |||
| Book Value Per Share | 34.18 X | |||
| Cash Flow From Operations | (45.61 M) | |||
| Short Ratio | 1.70 X | |||
| Earnings Per Share | (12.28) X | |||
| Price To Earnings To Growth | (0.03) X | |||
| Target Price | 1.5 | |||
| Beta | 1.1 | |||
| Market Capitalization | 8.2 M | |||
| Total Asset | 115.95 M | |||
| Retained Earnings | (451.06 M) | |||
| Working Capital | 88.07 M | |||
| Current Asset | 289 K | |||
| Current Liabilities | 1.02 M | |||
| Z Score | -5.73 | |||
| Net Asset | 115.95 M |
About Neoleukin Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neoleukin Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neoleukin Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neoleukin Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Neoleukin Stock
If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |